Global Glucagon Receptor Agonist Market Size was USD 1.12 Billion in 2025, this report covers Market growth, trend, opportunity and forecast from 2026-2032

The Glucagon Receptor Agonist market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.

1. Eli Lilly and Company:

   Eli Lilly and Company occupies a central position in the Glucagon Receptor Agonist market due to its deep heritage in diabetes and metabolic disease therapeutics. The company leverages a broad endocrinology portfolio, extensive real-world evidence, and long-standing relationships with diabetologists and primary care physicians to shape clinical practice patterns. Its involvement in glucagon receptor agonist research builds on its experience in incretin-based therapies and insulin, positioning it as a benchmark for clinical efficacy and safety expectations in this emerging class.

   In 2025, Eli Lilly’s Glucagon Receptor Agonist-related revenue is estimated at USD 0.22 billion with a market share of 19.50% . These figures indicate that Lilly is one of the largest stakeholders in a market projected by ReportMines to reach USD 1.12 billion in 2025 and expand to USD 5.63 billion by 2032 at a compound annual growth rate of 25.80%. This revenue and share profile reflect strong early adoption of its assets, robust formulary access, and effective integration into treatment algorithms for patients with type 2 diabetes and obesity-related metabolic disorders.

   Eli Lilly’s competitive differentiation in Glucagon Receptor Agonists is driven by its capabilities in large-scale phase III programs, advanced biomarker-driven patient segmentation, and integrated digital adherence solutions. The company deploys sophisticated market access tools, including outcomes-based contracts with payers, to reduce budget impact concerns and facilitate rapid inclusion in reimbursement lists. Its manufacturing scale and reliable global distribution network further enhance its bargaining power with group purchasing organizations and national health systems, enabling aggressive yet sustainable pricing strategies.

   Strategically, Lilly links its glucagon receptor agonist pipeline with its broader metabolic disease ecosystem, including combination regimens with GLP-1 receptor agonists and other incretin therapies. This allows the company to design differentiated clinical bundles targeting weight reduction, glycemic durability, and cardiovascular risk parameters. By generating robust comparative effectiveness data, Eli Lilly is able to defend premium positioning and limit competitive erosion from late-entrant generics and biosimilars once the class matures.

2. Novo Nordisk A/S:

   Novo Nordisk A/S is a foundational player in the Glucagon Receptor Agonist market, supported by its global leadership in diabetes care and obesity pharmacotherapy. The company’s established expertise in peptide engineering and incretin biology makes it a natural frontrunner in optimizing glucagon receptor agonist profiles for efficacy, safety, and dosing convenience. Its brand recognition among endocrinologists and its broad obesity franchise lend strong credibility to new entrants in this mechanism of action.

   For 2025, Novo Nordisk’s Glucagon Receptor Agonist portfolio is estimated to generate USD 0.25 billion in revenue with a market share of 22.30% . These figures suggest that Novo is likely the category leader or co-leader, capturing a significant portion of early demand as payers and clinicians prioritize companies with proven outcomes in weight loss and glycemic control. The company’s ability to convert existing GLP-1 users to next-generation combination regimens that incorporate glucagon receptor agonism further amplifies its revenue capture.

   Novo Nordisk differentiates itself through long-acting injectable and potentially oral formulations designed for high adherence and patient-friendly administration schedules. Its strategic advantage lies in large-scale cardiovascular outcomes trials and obesity-focused endpoints, which are especially relevant as payers increasingly link reimbursement to cardio-metabolic risk reduction. The company also invests heavily in medical education and real-world evidence registries that demonstrate the health-economic value of incremental HbA1c reduction and body weight improvements enabled by glucagon receptor agonists.

   From a market entry and expansion perspective, Novo Nordisk leverages strong reimbursement relationships and prior wins in GLP-1 and obesity agents to accelerate price negotiations for glucagon receptor agonist products. By bundling contracts across multiple metabolic therapies, the company can offer payers attractive total-cost-of-care packages while preserving margin on differentiated assets. This strategy reinforces its dominant position as the market grows from USD 1.41 billion in 2026 towards multi-billion-dollar status by 2032.

3. Pfizer Inc.:

   Pfizer Inc. is emerging as a significant challenger in the Glucagon Receptor Agonist space, using its scale in small molecule and biologics development to diversify beyond its traditional cardiovascular and immunology franchises. While not historically the leading diabetes company, Pfizer’s strong capabilities in medicinal chemistry and oral formulations create opportunities for differentiated glucagon receptor agonist candidates, particularly in tablet form that could appeal to patients reluctant to use injectables.

   In 2025, Pfizer’s Glucagon Receptor Agonist-related revenue is estimated at USD 0.09 billion with a market share of 8.30% . This indicates a solid but not dominant position, reflecting a company still in the scaling phase of its glucagon receptor portfolio. The figures suggest Pfizer is competitive enough to be relevant in formulary discussions, yet it must still prove long-term differentiation against metabolically focused incumbents such as Novo Nordisk and Eli Lilly.

   Pfizer’s competitive advantages include global regulatory experience, strong primary care promotional infrastructure, and the ability to run parallel development programs in multiple indications such as non-alcoholic steatohepatitis, obesity, and type 2 diabetes. If the company advances an oral glucagon receptor agonist or a fixed-dose combination with other cardiometabolic agents, it could rewrite the convenience expectations in this class. Its partnerships with digital health platforms and remote monitoring solutions also support value-based care models that track treatment impact in real time.

   From a strategic standpoint, Pfizer is likely to pursue co-development or co-marketing alliances to accelerate uptake in regions where its diabetes presence is less mature. Its pricing philosophy in glucagon receptor agonists will probably emphasize competitive list prices combined with volume-based discounts for large integrated delivery networks. This approach could allow Pfizer to gain incremental share from cost-sensitive payers and health systems seeking alternatives to premium incumbents, particularly in emerging markets.

4. AstraZeneca plc:

   AstraZeneca plc holds an important role in the Glucagon Receptor Agonist market due to its established position in type 2 diabetes and cardiovascular-renal-metabolic care. Building on the success of its SGLT2 inhibitor and other metabolic therapies, the company is well positioned to integrate glucagon receptor agonists into multi-pathway treatment strategies targeting glucose control, weight management, and cardiorenal protection. Its focus on holistic cardio-renal-metabolic outcomes resonates strongly with health systems pursuing integrated disease management.

   For 2025, AstraZeneca’s glucagon receptor agonist segment is estimated to deliver USD 0.07 billion in revenue, corresponding to a market share of 6.30% . These figures point to a meaningful, though not leading, presence and suggest that AZ is selectively focusing on high-value patient segments where additive benefits over existing therapies are most pronounced. The company’s share reflects a strategy of embedding glucagon receptor agonists within broader combination regimens rather than chasing volume at the expense of profitability.

   AstraZeneca’s strategic advantage lies in its expertise at designing long-term outcomes trials that capture renal and cardiovascular benefits beyond glycemic control. This is particularly relevant as glucagon receptor agonists are evaluated not only on HbA1c reduction but also on their impact on hepatic fat content, body composition, and cardio-metabolic risk markers. The company’s strong relationships with nephrologists and cardiologists enable cross-specialty adoption, which is crucial for high-risk patients who benefit from multi-factorial interventions.

   Commercially, AstraZeneca often deploys a coordinated field force that addresses endocrinologists, cardiologists, and nephrologists with integrated messaging around cardio-renal-metabolic protection. Combined with health-economic models that highlight hospitalization avoidance and slower progression of chronic kidney disease, this strategy can support premium reimbursement positioning for its glucagon receptor agonist offerings. Over time, such an approach could allow AstraZeneca to expand its share as payers increasingly prioritize therapies with broad systemic benefits.

5. Sanofi:

   Sanofi maintains a long-standing presence in the diabetes market, and this heritage extends into its role in the Glucagon Receptor Agonist segment. Although the company has faced competitive pressure in basal insulin and GLP-1 segments, its global reach and experience in large-scale diabetes management programs give it a solid foundation for introducing new glucagon receptor-targeted therapeutics. Sanofi’s relationships with public health systems and its footprint in emerging markets are particularly valuable for market expansion beyond early-adopting regions.

   In 2025, Sanofi’s Glucagon Receptor Agonist-related revenue is estimated at USD 0.06 billion with a market share of 5.40% . These numbers reflect a modest yet strategically significant position, indicating that Sanofi is active in the segment but not yet among the top-tier revenue leaders. The company’s presence signals to payers and providers that multiple global incumbents are validating this mechanism, which supports overall class adoption.

   Sanofi’s strategic differentiation is likely to center on combining glucagon receptor agonists with its existing insulin and GLP-1 assets, potentially offering flexible titration regimens tailored to diverse patient phenotypes. The company also brings strong pharmacovigilance and long-term safety monitoring capabilities, which can be crucial for payers evaluating new mechanisms in high-prevalence diseases. By emphasizing real-world adherence data and patient support programs, Sanofi can mitigate concerns around treatment complexity and injection burden.

   From a commercial perspective, Sanofi often competes through competitive net pricing and robust disease management services rather than purely on product novelty. In the glucagon receptor space, this could translate into bundled offerings with insulin titration support, educational platforms, and telemedicine integration. Such an approach can help Sanofi capture a significant portion of volume among cost-sensitive payers while retaining differentiation on service and support rather than solely on molecule characteristics.

6. Roche Holding AG:

   Roche Holding AG approaches the Glucagon Receptor Agonist market from a diagnostics and precision medicine angle rather than as a traditional diabetes drug incumbent. While its direct exposure to glucagon receptor agonist therapeutics is more limited than peers, Roche’s leadership in glucose monitoring, continuous glucose sensors, and companion diagnostics positions it as an influential ecosystem player. Any Roche-linked glucagon receptor agonist initiatives are likely to be tightly integrated with data-driven disease management tools.

   For 2025, Roche’s Glucagon Receptor Agonist-related revenue is estimated at USD 0.02 billion with a market share of 1.80% . These relatively small figures indicate that Roche’s participation is niche and possibly focused on co-development projects, licensing deals, or targeted regional commercialization rather than broad, global rollouts. Nevertheless, its presence underscores an opportunity for convergence between therapeutics and digital diagnostics in this market.

   Roche’s strategic advantage lies in its ability to generate high-resolution metabolic data that can guide optimal use of glucagon receptor agonists. For instance, integrating continuous glucose monitoring with liver function metrics and weight-tracking tools can help clinicians tailor dosing regimens and identify candidates for combination therapy. This aligns well with the increasing interest in personalized metabolic treatment pathways where therapies are selected based on predictive biomarkers and treatment response patterns.

   Looking ahead, Roche could amplify its role in the glucagon receptor space by forming partnerships with pharmaceutical companies developing these agents, offering companion diagnostics, adherence analytics, and outcome dashboards. Such collaborations would give drug developers access to sophisticated data infrastructures, while Roche would gain a foothold in therapy-linked revenue sharing and value-based care arrangements tied to glucagon receptor agonist performance.

7. Boehringer Ingelheim International GmbH:

   Boehringer Ingelheim International GmbH is a key player in the broader diabetes and cardiovascular markets and translates this expertise into emerging opportunities around Glucagon Receptor Agonists. Its successful history with SGLT2 inhibitors and cardiometabolic co-marketing partnerships demonstrates its ability to scale innovative therapies across primary care and specialty channels. This background provides a strong launchpad for glucagon receptor-focused assets, especially in combination regimens.

   In 2025, Boehringer Ingelheim’s glucagon receptor agonist revenue is estimated at USD 0.05 billion with a market share of 4.50% . These values suggest a growing presence with meaningful upside as the market compounds at 25.80% annually through 2032. The company is large enough to be recognized by payers and clinicians yet still has significant headroom to expand its footprint as evidence for the class accumulates.

   Boehringer’s competitive advantages include its experience in designing dual-purpose trials that capture both glycemic and cardiovascular outcomes, which is increasingly important for payer decision-making. The company also maintains strong alliances with other pharmaceutical firms, a model that could be replicated for co-development or co-promotion of glucagon receptor agonists. Such alliances can accelerate penetration in regions where Boehringer’s direct presence in diabetes is less established.

   On the commercial side, Boehringer Ingelheim tends to emphasize medical education and guideline engagement, investing in scientific exchange with key opinion leaders across cardiology and endocrinology. This focus helps build clinical confidence in new mechanisms like glucagon receptor agonism. When combined with targeted patient support programs that address adherence, hypoglycemia risk perception, and weight management motivation, the company can systematically grow its share within this expanding therapeutic class.

8. Amgen Inc.:

   Amgen Inc. participates in the Glucagon Receptor Agonist market primarily through its biologics and metabolic research capabilities rather than as a traditional diabetes incumbent. Known for its work in lipid management and bone health, Amgen is diversifying into metabolic and obesity-oriented mechanisms, which may include glucagon receptor agonism as part of broader weight and energy balance strategies. Its strong biologics engineering platform allows for exploration of long-acting injectable or antibody-based modulation of glucagon pathways.

   For 2025, Amgen’s glucagon receptor agonist-related revenue is estimated at USD 0.03 billion with a market share of 2.70% . These values indicate an early-stage or niche position, likely focused on high-value patient subsets or clinical development programs rather than full-scale commercial deployment. The figures reflect Amgen’s strategy of testing innovative mechanisms thoroughly before committing to large commercial infrastructures in a new disease area.

   Amgen’s core competitive differentiation lies in its expertise in protein engineering, long half-life biologics, and sophisticated manufacturing of complex molecules. These capabilities could enable a glucagon receptor agonist asset with extended dosing intervals, potentially monthly or longer, which would differentiate strongly from weekly or daily regimens. A less frequent dosing schedule might be especially appealing to patients with obesity-related metabolic dysfunction who struggle with treatment adherence.

   Strategically, Amgen is likely to pursue targeted market entry through specialty metabolic clinics and tertiary centers that manage complex obesity and cardiovascular risk profiles. These centers are generally more open to innovative biologics and willing to participate in outcomes-based contracting. Over time, if Amgen’s glucagon receptor agonist assets demonstrate substantial weight reduction and cardiometabolic benefits, the company could scale beyond niche segments and secure broader payer coverage in line with other high-impact obesity treatments.

9. Johnson & Johnson:

   Johnson & Johnson engages with the Glucagon Receptor Agonist market through its pharmaceuticals business, which has experience in metabolic disorders alongside its wide-ranging portfolio in immunology, oncology, and neuroscience. While not the most prominent name in diabetes care compared with specialized incumbents, J&J’s extensive clinical development infrastructure and global commercialization capabilities allow it to compete effectively in emerging metabolic mechanisms, including those centered on glucagon pathways.

   In 2025, Johnson & Johnson’s glucagon receptor agonist revenue is estimated at USD 0.04 billion with a market share of 3.60% . These metrics suggest a meaningful but mid-tier position in a rapidly expanding market. The company is positioned to grow its share if it can demonstrate differentiated outcomes, particularly in obesity co-morbidities, or if it pursues strategic in-licensing or acquisition of promising glucagon receptor agonist assets.

   J&J’s strengths include integrated evidence generation, robust health-economic modeling, and expertise in negotiating complex value-based contracts with large payers and integrated delivery networks. The company is adept at structuring agreements that tie reimbursement to measurable improvements in hospitalization rates, quality-of-life metrics, and long-term complications, which aligns well with the multifactorial benefits expected from glucagon receptor agonists. This approach is likely to resonate with payers grappling with rising spending on obesity and type 2 diabetes therapies.

   From a commercial strategy standpoint, Johnson & Johnson can leverage its global health partnerships and presence in public healthcare tenders to position glucagon receptor agonists as part of comprehensive cardiometabolic care programs. By integrating patient education, digital adherence tools, and remote monitoring solutions, the company can improve persistence on therapy and build a strong real-world data set that supports further market expansion and premium reimbursement negotiations.

10. Merck & Co., Inc.:

    Merck & Co., Inc. is an established player in type 2 diabetes, and its legacy in DPP-4 inhibition and cardiometabolic care naturally extends into interest in Glucagon Receptor Agonists. The company’s established primary care networks and experience with oral metabolic agents give it a distinct perspective on the potential for oral or co-formulated glucagon receptor modulators. Merck’s reputation for well-characterized safety profiles adds credibility to its efforts in this new mechanism.

    For 2025, Merck’s glucagon receptor agonist-related revenue is estimated at USD 0.05 billion with a market share of 4.50% . These figures place Merck on par with several mid-level competitors and reflect a balanced strategy of participation without overexposure in a still-evolving class. Given the market’s projected expansion to USD 1.41 billion in 2026 and further to USD 5.63 billion in 2032, Merck has room to scale if clinical data are compelling.

    Merck’s competitive advantage lies in designing therapies that integrate seamlessly into primary care workflows, emphasizing safety, oral administration, and straightforward titration. If it advances oral glucagon receptor agonists or combination tablets that pair with existing agents, Merck could capture patients earlier in the disease course before injectables become necessary. This positioning would be highly attractive for health systems aiming to delay progression to more complex regimens.

    The company also has strong capabilities in post-marketing surveillance and pharmacoepidemiology, which can be instrumental in building long-term safety narratives around glucagon receptor modulation. By leveraging observational data and claims analyses, Merck can demonstrate reductions in complications such as hepatic steatosis, cardiovascular events, or hospitalization rates. These insights would support compelling value dossiers that help secure broad reimbursement and inclusion in clinical guidelines.

11. Viking Therapeutics, Inc.:

    Viking Therapeutics, Inc. is a specialized biotechnology company with a strong focus on metabolic and liver diseases, making it highly relevant to the Glucagon Receptor Agonist market. The company’s pipeline emphasizes mechanisms that impact energy expenditure, hepatic fat accumulation, and weight regulation, and glucagon receptor agonism aligns closely with these priorities. As a clinical-stage innovator, Viking plays a pivotal role in pushing the boundaries of efficacy expectations in obesity and related metabolic conditions.

    In 2025, Viking Therapeutics’ glucagon receptor agonist revenue is estimated at USD 0.03 billion with a market share of 2.70% . This reflects early commercialization or partnership-driven revenue rather than mature, large-scale sales. Nevertheless, the company’s share is notable for a smaller biotech and underscores the high strategic value that payers and potential partners place on novel, high-efficacy candidates in this mechanism.

    Viking’s competitive differentiation stems from its focus on obesity and non-alcoholic steatohepatitis, where glucagon receptor agonists may offer dual benefits in weight reduction and hepatic fat modulation. By designing trials with robust imaging endpoints, liver histology measures, and cardiometabolic markers, the company can demonstrate multi-organ benefits that go beyond traditional glycemic outcomes. This data-rich approach positions Viking as an attractive partner for larger pharmaceutical companies seeking to strengthen their metabolic portfolios.

    From a strategic planning perspective, Viking is likely to monetize its glucagon receptor assets through out-licensing, co-development arrangements, or regional commercialization partnerships rather than building a full global sales infrastructure. This capital-efficient model enables it to focus on scientific innovation and late-stage clinical execution while leveraging the distribution and market access capabilities of larger partners. Investors and strategic buyers will closely watch Viking’s data readouts as key value inflection points in the broader glucagon receptor agonist landscape.

12. Zealand Pharma A/S:

    Zealand Pharma A/S is a peptide-focused biotechnology company with deep expertise in designing and optimizing peptide-based therapeutics, including those targeting metabolic pathways. This specialization makes Zealand an important innovator in the Glucagon Receptor Agonist market, particularly for dual or triple agonists that combine glucagon receptor activity with GLP-1 or GIP receptor stimulation. Such multi-agonist constructs are at the forefront of next-generation obesity and diabetes therapy development.

    In 2025, Zealand Pharma’s glucagon receptor agonist-related revenue is estimated at USD 0.04 billion with a market share of 3.60% . These numbers likely reflect a mix of direct product revenue and milestone or collaboration payments from larger partners. For a specialized biotech, this level of participation is meaningful and highlights the strategic importance of Zealand’s technology platform to the overall evolution of the market.

    Zealand’s strategic advantage lies in its ability to rapidly iterate peptide designs to optimize receptor selectivity, pharmacokinetics, and tolerability. This enables the creation of glucagon receptor agonist combinations with finely tuned efficacy and side-effect profiles that can be customized for specific patient segments, such as those with severe obesity or co-existing hepatic disease. The company’s history of forming partnerships with major pharmaceutical firms gives it a proven pathway for translating its research into global commercial products.

    Looking ahead, Zealand is well positioned to benefit from the market’s anticipated expansion to USD 5.63 billion by 2032, as larger companies seek access to its multi-agonist platforms to differentiate their portfolios. Investors evaluating Zealand should focus on the breadth and maturity of its glucagon receptor-containing pipeline, the strength of its patent estate, and the potential for high-value licensing deals that can generate substantial non-dilutive funding and long-term royalty streams.

13. Hanmi Pharmaceutical Co., Ltd.:

    Hanmi Pharmaceutical Co., Ltd., based in South Korea, has built a strong reputation in long-acting formulation technologies and has actively pursued innovative diabetes and obesity candidates. This makes Hanmi a notable regional and increasingly global participant in the Glucagon Receptor Agonist market. The company has a track record of licensing its assets to multinational partners, enabling broad geographic reach for its innovations.

    For 2025, Hanmi’s glucagon receptor agonist-related revenue is estimated at USD 0.03 billion with a market share of 2.70% . These figures indicate a modest yet strategically important presence, particularly given Hanmi’s focus on technology licensing and co-development rather than direct commercialization in all regions. The revenue mix likely includes upfront payments, milestones, and early sales from territories where Hanmi maintains direct commercial operations.

    Hanmi’s competitive differentiation is anchored in its proprietary long-acting drug delivery platforms, which can be applied to glucagon receptor agonist peptides or conjugates to extend dosing intervals. This is highly attractive in obesity and chronic metabolic diseases, where patient adherence is a consistent challenge. By enabling once-weekly or even less frequent dosing, Hanmi’s technologies can meaningfully improve treatment persistence and patient satisfaction.

    Strategically, Hanmi is likely to focus on securing additional global partners for its glucagon receptor-related assets, particularly in North America and Europe. Such collaborations would allow the company to capture a significant portion of future market growth while mitigating commercialization risk. For investors and potential partners, the key evaluation factors include the robustness of Hanmi’s clinical data, the scalability of its manufacturing capabilities, and the strength of its intellectual property around long-acting glucagon receptor formulations.

14. Altimmune, Inc.:

    Altimmune, Inc. is an emerging biotechnology company focused on metabolic disease and obesity, with an emphasis on innovative mechanisms to reduce body weight and improve cardiometabolic health. This focus places Altimmune squarely within the strategic core of the Glucagon Receptor Agonist market, where weight reduction and energy expenditure are critical clinical outcomes. The company’s assets often explore combination or multi-pathway approaches that can complement glucagon receptor agonism.

    In 2025, Altimmune’s glucagon receptor agonist-related revenue is estimated at USD 0.02 billion with a market share of 1.80% . These early-stage figures are typical for a growth-stage biotech that is transitioning from pure R&D focus to initial monetization through partnerships, milestones, or limited commercial activity. The revenue level underscores the high strategic interest in Altimmune’s assets from larger companies seeking differentiated obesity and metabolic treatments.

    Altimmune’s competitive advantage lies in its capacity to design therapies that meaningfully impact body weight and metabolic markers with favorable tolerability profiles. When combined with or compared against glucagon receptor agonists, such therapeutics can either enhance or compete with this mechanism, creating strategic optionality for the company in terms of partnering or independent commercialization. Altimmune’s lean organizational structure also supports rapid clinical decision-making and adaptive trial designs.

    From a strategic investment standpoint, Altimmune represents a high-upside, higher-risk play within the glucagon receptor agonist ecosystem. Its valuation and partnering potential will be strongly influenced by mid- and late-stage trial readouts in obesity and metabolic indications. If its assets demonstrate synergistic effects with glucagon receptor agonists or superior standalone efficacy, Altimmune could become a prime acquisition target or a long-term licensing partner for established metabolic players.

15. Amphastar Pharmaceuticals, Inc.:

    Amphastar Pharmaceuticals, Inc. is traditionally recognized for its injectable, inhalation, and generic products, including emergency glucagon formulations. This background makes Amphastar a relevant but differentiated participant in the Glucagon Receptor Agonist market, with capabilities that straddle both branded innovation and cost-effective manufacturing. Its experience with glucagon products provides a scientific and regulatory foundation for engaging with glucagon receptor-targeted therapies.

    In 2025, Amphastar’s glucagon receptor agonist-related revenue is estimated at USD 0.01 billion with a market share of 0.90% . These figures indicate a relatively small but strategic position, likely focused on specific formulations, regional markets, or early pipeline assets. Amphastar’s role may evolve as the market matures and opportunities arise for generic or follow-on versions of glucagon receptor agonists once patents expire.

    Amphastar’s competitive advantage lies in its expertise in sterile injectables manufacturing, cost-efficient production, and navigating complex regulatory pathways for both generics and specialty products. This positions the company to eventually supply lower-cost alternatives or niche formulations of glucagon receptor agonists tailored to hospital use, emergency kits, or specific patient segments. Such a role can become increasingly important as payers seek to manage the long-term budget impact of a rapidly expanding class.

    Strategically, Amphastar may pursue licensing opportunities, contract manufacturing arrangements, or co-development deals with companies that own original glucagon receptor agonist molecules but lack large-scale injectable manufacturing capacity. This would allow Amphastar to leverage its operational strengths while participating in the growth of a market expected to more than quadruple in value between 2025 and 2032. For stakeholders evaluating Amphastar, the key factors include its ability to secure partnerships, maintain high-quality manufacturing standards, and navigate pricing pressures in a competitive injectable landscape.